1. Home
  2. CBIO vs FOA Comparison

CBIO vs FOA Comparison

Compare CBIO & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • FOA
  • Stock Information
  • Founded
  • CBIO 2003
  • FOA 2013
  • Country
  • CBIO United States
  • FOA United States
  • Employees
  • CBIO N/A
  • FOA N/A
  • Industry
  • CBIO
  • FOA Finance Companies
  • Sector
  • CBIO
  • FOA Finance
  • Exchange
  • CBIO Nasdaq
  • FOA Nasdaq
  • Market Cap
  • CBIO 308.0M
  • FOA 248.8M
  • IPO Year
  • CBIO N/A
  • FOA N/A
  • Fundamental
  • Price
  • CBIO $12.60
  • FOA $21.92
  • Analyst Decision
  • CBIO Strong Buy
  • FOA Buy
  • Analyst Count
  • CBIO 3
  • FOA 2
  • Target Price
  • CBIO $25.67
  • FOA $27.50
  • AVG Volume (30 Days)
  • CBIO 138.8K
  • FOA 71.2K
  • Earning Date
  • CBIO 08-23-2025
  • FOA 08-05-2025
  • Dividend Yield
  • CBIO N/A
  • FOA N/A
  • EPS Growth
  • CBIO N/A
  • FOA N/A
  • EPS
  • CBIO N/A
  • FOA 3.94
  • Revenue
  • CBIO N/A
  • FOA $429,184,000.00
  • Revenue This Year
  • CBIO N/A
  • FOA $21.89
  • Revenue Next Year
  • CBIO N/A
  • FOA $8.91
  • P/E Ratio
  • CBIO N/A
  • FOA $5.63
  • Revenue Growth
  • CBIO N/A
  • FOA 155.35
  • 52 Week Low
  • CBIO $11.06
  • FOA $6.83
  • 52 Week High
  • CBIO $21.40
  • FOA $32.40
  • Technical
  • Relative Strength Index (RSI)
  • CBIO N/A
  • FOA 39.33
  • Support Level
  • CBIO N/A
  • FOA $23.50
  • Resistance Level
  • CBIO N/A
  • FOA $25.37
  • Average True Range (ATR)
  • CBIO 0.00
  • FOA 0.97
  • MACD
  • CBIO 0.00
  • FOA -0.25
  • Stochastic Oscillator
  • CBIO 0.00
  • FOA 3.90

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About FOA Finance of America Companies Inc.

Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.

Share on Social Networks: